Biocon Biologics Completes $3 Billion Acquisition of Viatris’ BiosimilarsDecember 12th 2022
The acquisition provides Biocon Biologics with eight commercial biosimilars, and is part of Viatris’ efforts to pay down debt related to phase 1 research and the company’s acquisition of two ophthalmology businesses.
FDA Accepts sBLA for Evkeeza for Children with Rare High CholesterolNovember 30th 2022
If approved, Evkeeza would be the first treatment to help children as young as 5 years old control high LDL cholesterol caused by homozygous familial hypercholesterolemia. The FDA target action date is March 30, 2023.